Pillsbury Advises Humaneva, Inc. in Entering Into $50 Million Minority Stake Investment With Viking Global Investors

Pillsbury advised Humaneva, Inc., a spin-off of wholesale pharmaceutical distributor NEUCA S.A., in entering into a $50 million a minority stake investment agreement with Viking Global Investors.

Humaneva, Inc., the parent company of Pratia, Kapadi and Hyggio—leaders in providing integrated clinical trial solutions—aims to accelerate the evolution of its business model.

In addition to the partnership’s goal of expanding into the American and Asian-Pacific regions, Humaneva, Inc. plans to strengthen its proprietary technology offerings, focusing on eSource solutions, data integration and analytics, with the goal of broadening access to clinical research as a care option worldwide. To learn more about the transaction, click here.

The Silicon Valley-based Pillsbury deal team was led by Corporate partner Stan Lewandowski and included Executive Compensation & Benefits partner Laura McDaniels, Corporate associate Ann Kim and legal assistant Adam Perry.